{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T22:03:28Z","timestamp":1792706608132,"version":"4.5.0"},"reference-count":29,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2022,5,1]]},"DOI":"10.1001\/jamaoncol.2021.3547","type":"journal-article","created":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T18:38:48Z","timestamp":1648751928000},"page":"740","source":"Crossref","is-referenced-by-count":55,"title":["Efficacy and Safety of TRC105 Plus Pazopanib vs Pazopanib Alone for Treatment of Patients With Advanced Angiosarcoma"],"prefix":"10.1001","volume":"8","author":[{"given":"Robin L.","family":"Jones","sequence":"first","affiliation":[{"name":"Sarcoma Unit, Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod","family":"Ravi","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew S.","family":"Brohl","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center, Tampa, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sant","family":"Chawla","sequence":"additional","affiliation":[{"name":"Sarcoma Oncology Research Center, Santa Monica, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen N.","family":"Ganjoo","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Medicine, Stanford University, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Italiano","sequence":"additional","affiliation":[{"name":"Bergonie Institute, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Attia","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Jacksonville, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa A.","family":"Burgess","sequence":"additional","affiliation":[{"name":"University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Thornton","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee D.","family":"Cranmer","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Medicine, University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maggie Chon U.","family":"Cheang","sequence":"additional","affiliation":[{"name":"Sarcoma Unit, Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyun","family":"Liu","sequence":"additional","affiliation":[{"name":"Cytel Clinical Research, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liz","family":"Robertson","sequence":"additional","affiliation":[{"name":"TRACON Pharmaceuticals, Inc, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonne","family":"Adams","sequence":"additional","affiliation":[{"name":"TRACON Pharmaceuticals, Inc, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Theuer","sequence":"additional","affiliation":[{"name":"TRACON Pharmaceuticals, Inc, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert G.","family":"Maki","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"11","key":"coi210054r1","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.3390\/cancers12113321","article-title":"Optimal clinical management and the molecular biology of angiosarcomas.","volume":"12","author":"Chen","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"4","key":"coi210054r2","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2020-000787","article-title":"Evaluation of the use and efficacy of (neo)adjuvant chemotherapy in angiosarcoma: a multicentre study.","volume":"5","author":"Constantinidou","year":"2020","journal-title":"ESMO Open"},{"issue":"2","key":"coi210054r3","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1093\/annonc\/mdr138","article-title":"Metastatic angiosarcomas: doxorubicin-based regimens, weekly paclitaxel and metastasectomy significantly improve the outcome.","volume":"23","author":"Penel","year":"2012","journal-title":"Ann Oncol"},{"issue":"16","key":"coi210054r4","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1016\/j.ejca.2008.07.037","article-title":"Paclitaxel in patients with advanced angiosarcomas of soft tissue: a retrospective study of the EORTC Soft Tissue and Bone Sarcoma Group.","volume":"44","author":"Schlemmer","year":"2008","journal-title":"Eur J Cancer"},{"issue":"32","key":"coi210054r5","doi-asserted-by":"publisher","first-page":"5269","DOI":"10.1200\/JCO.2008.17.3146","article-title":"Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study.","volume":"26","author":"Penel","year":"2008","journal-title":"J Clin Oncol"},{"issue":"13","key":"coi210054r6","doi-asserted-by":"publisher","first-page":"3330","DOI":"10.1002\/cncr.26599","article-title":"Comparison of doxorubicin and weekly paclitaxel efficacy in metastatic angiosarcomas.","volume":"118","author":"Italiano","year":"2012","journal-title":"Cancer"},{"issue":"25","key":"coi210054r7","doi-asserted-by":"publisher","first-page":"2797","DOI":"10.1200\/JCO.2015.60.8505","article-title":"Paclitaxel given once per week with or without bevacizumab in patients with advanced angiosarcoma: a randomized phase II trial.","volume":"33","author":"Ray-Coquard","year":"2015","journal-title":"J Clin Oncol"},{"issue":"2","key":"coi210054r8","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1093\/annonc\/mdr066","article-title":"Gemcitabine in advanced angiosarcoma: a retrospective case series analysis from the Italian Rare Cancer Network.","volume":"23","author":"Stacchiotti","year":"2012","journal-title":"Ann Oncol"},{"issue":"2","key":"coi210054r9","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1634\/theoncologist.2011-0237","article-title":"Sorafenib for patients with advanced angiosarcoma: a phase II trial from the French Sarcoma Group (GSF\/GETO).","volume":"17","author":"Ray-Coquard","year":"2012","journal-title":"Oncologist"},{"issue":"1","key":"coi210054r10","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1080\/0284186X.2016.1234068","article-title":"Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis.","volume":"56","author":"Koll\u00e1r","year":"2017","journal-title":"Acta Oncol"},{"key":"coi210054r11","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ejca.2019.07.024","article-title":"Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours.","volume":"120","author":"Jones","year":"2019","journal-title":"Eur J Cancer"},{"issue":"9829","key":"coi210054r12","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","article-title":"Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial.","volume":"379","author":"van der Graaf","year":"2012","journal-title":"Lancet"},{"issue":"6","key":"coi210054r13","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.4049\/jimmunol.141.6.1925","article-title":"Identification of a human endothelial cell antigen with monoclonal antibody 44G4 produced against a pre-B leukemic cell line.","volume":"141","author":"Gougos","year":"1988","journal-title":"J Immunol"},{"issue":"7","key":"coi210054r14","first-page":"1031","article-title":"Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin.","volume":"3","author":"Seon","year":"1997","journal-title":"Clin Cancer Res"},{"issue":"27","key":"coi210054r15","doi-asserted-by":"publisher","first-page":"19027","DOI":"10.1016\/S0021-9258(18)41732-2","article-title":"Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells.","volume":"267","author":"Cheifetz","year":"1992","journal-title":"J Biol Chem"},{"issue":"5419","key":"coi210054r16","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1126\/science.284.5419.1534","article-title":"Defective angiogenesis in mice lacking endoglin.","volume":"284","author":"Li","year":"1999","journal-title":"Science"},{"issue":"12","key":"coi210054r17","first-page":"1623","article-title":"Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy.","volume":"1","author":"Burrows","year":"1995","journal-title":"Clin Cancer Res"},{"issue":"11","key":"coi210054r18","first-page":"4221","article-title":"Differential vascular and transcriptional responses to anti-vascular endothelial growth factor antibody in orthotopic human pancreatic cancer xenografts.","volume":"9","author":"Bockhorn","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"13","key":"coi210054r19","doi-asserted-by":"publisher","first-page":"4601","DOI":"10.1158\/0008-5472.CAN-2879-2","article-title":"Regional effects of an antivascular endothelial growth factor receptor monoclonal antibody on receptor phosphorylation and apoptosis in human 253J B-V bladder cancer xenografts.","volume":"64","author":"Davis","year":"2004","journal-title":"Cancer Res"},{"issue":"5","key":"coi210054r20","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1007\/s10637-014-0129-y","article-title":"Effects of the combination of TRC105 and bevacizumab on endothelial cell biology.","volume":"32","author":"Liu","year":"2014","journal-title":"Invest New Drugs"},{"issue":"3","key":"coi210054r21","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1084\/jem.20120662","article-title":"Deficiency for endoglin in tumor vasculature weakens the endothelial barrier to metastatic dissemination.","volume":"210","author":"Anderberg","year":"2013","journal-title":"J Exp Med"},{"issue":"1","key":"coi210054r22","doi-asserted-by":"crossref","first-page":"B237","DOI":"10.1158\/1535-7163.TARG-13-B237","article-title":"Abstract B237: CD105: a therapeutic target for sarcomas.","volume":"12","author":"Fritchie","year":"2013","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"coi210054r23","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1007\/s00262-005-0691-4","article-title":"Antiangiogenic chimeric anti-endoglin (CD105) antibody: pharmacokinetics and immunogenicity in nonhuman primates and effects of doxorubicin.","volume":"55","author":"Shiozaki","year":"2006","journal-title":"Cancer Immunol Immunother"},{"issue":"2","key":"coi210054r25","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"1","key":"coi210054r26","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1093\/annonc\/mdy464","article-title":"An adaptive population enrichment phase III trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma (TAPPAS trial).","volume":"30","author":"Mehta","year":"2019","journal-title":"Ann Oncol"},{"issue":"2","key":"coi210054r27","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41591-019-0749-z","article-title":"The Angiosarcoma Project: enabling genomic and clinical discoveries in a rare cancer through patient-partnered research.","volume":"26","author":"Painter","year":"2020","journal-title":"Nat Med"},{"issue":"3","key":"coi210054r28","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s00280-015-2689-8","article-title":"Alliance A091103 a phase II study of the angiopoietin 1 and 2 peptibody trebananib for the treatment of angiosarcoma.","volume":"75","author":"D\u2019Angelo","year":"2015","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"coi210054r29","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1093\/annonc\/mds237","article-title":"An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas.","volume":"24","author":"Agulnik","year":"2013","journal-title":"Ann Oncol"},{"key":"coi210054r24","author":"Sankhala"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2790727\/jamaoncology_jones_2022_oi_210054_1652478721.92714.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T01:08:49Z","timestamp":1675127329000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2790727"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2022,5,1]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2021.3547","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.741927285.793592758","asserted-by":"object"}]},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5,1]]}}}